Moderna’s mRNA Flu Vaccine Approved | Boston News

Moderna just landed FDA approval for its groundbreaking mRNA flu vaccine, mFLUSIVA — the first of its kind for people 50 and older. Built on the same tech that revolutionized COVID-19 vaccines, this innovation could reshape seasonal flu protection. After some back-and-forth with regulators over trial design, Moderna adjusted its strategy to ensure safety and efficacy, especially for seniors. The vaccine is expected to hit shelves in 2026–2027, but its potential to outperform current options and accelerate flu prevention makes it a major milestone in medical science. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/20b640b69667a03e